These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 22110426)

  • 1. GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration.
    Gómez-Sintes R; Hernández F; Lucas JJ; Avila J
    Front Mol Neurosci; 2011; 4():45. PubMed ID: 22110426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent.
    Gómez-Sintes R; Lucas JJ
    PLoS One; 2013; 8(8):e70952. PubMed ID: 23940673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.
    Gómez-Sintes R; Lucas JJ
    J Clin Invest; 2010 Jul; 120(7):2432-45. PubMed ID: 20530871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice.
    Gómez-Sintes R; Hernández F; Bortolozzi A; Artigas F; Avila J; Zaratin P; Gotteland JP; Lucas JJ
    EMBO J; 2007 Jun; 26(11):2743-54. PubMed ID: 17510631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.
    Engel T; Hernández F; Avila J; Lucas JJ
    J Neurosci; 2006 May; 26(19):5083-90. PubMed ID: 16687499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A longitudinal FDG-PET study of transgenic mice overexpressing GSK- 3β in the brain.
    de Cristóbal J; Garcia-Garcia L; Delgado M; Pozo MA; Medina M
    Curr Alzheimer Res; 2014 Feb; 11(2):175-81. PubMed ID: 23905999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.
    Serenó L; Coma M; Rodríguez M; Sánchez-Ferrer P; Sánchez MB; Gich I; Agulló JM; Pérez M; Avila J; Guardia-Laguarta C; Clarimón J; Lleó A; Gómez-Isla T
    Neurobiol Dis; 2009 Sep; 35(3):359-67. PubMed ID: 19523516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disparate Effects of Lithium and a GSK-3 Inhibitor on Neuronal Oscillatory Activity in Prefrontal Cortex and Hippocampus.
    Nguyen T; Fan T; George SR; Perreault ML
    Front Aging Neurosci; 2017; 9():434. PubMed ID: 29375364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of JGK-263 as a new glycogen synthase kinase-3β inhibitor on extrinsic apoptosis pathway in motor neuronal cells.
    Jeon GS; Kim JE; Ahn SW; Park KS; Hong YH; Ye IH; Park JS; Kim SH; Lee KW; Kim SM; Sung JJ
    Biochem Biophys Res Commun; 2013 Sep; 439(2):309-14. PubMed ID: 23899525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease.
    Fernández-Nogales M; Hernández F; Miguez A; Alberch J; Ginés S; Pérez-Navarro E; Lucas JJ
    Hum Mol Genet; 2015 Sep; 24(17):5040-52. PubMed ID: 26082469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extrinsic Apoptosis Pathway Altered by Glycogen Synthase Kinase-3
    Kim JE; Lim JH; Jeon GS; Shin JY; Ahn SW; Kim SH; Lee KW; Hong YH; Sung JJ
    Biomed Res Int; 2017; 2017():4163839. PubMed ID: 29082245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neuroprotective effect of the GSK-3β inhibitor and influence on the extrinsic apoptosis in the ALS transgenic mice.
    Ahn SW; Kim JE; Park KS; Choi WJ; Hong YH; Kim SM; Kim SH; Lee KW; Sung JJ
    J Neurol Sci; 2012 Sep; 320(1-2):1-5. PubMed ID: 22698482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycogen synthase kinase-3beta activity plays very important roles in determining the fate of oxidative stress-inflicted neuronal cells.
    Lee KY; Koh SH; Noh MY; Park KW; Lee YJ; Kim SH
    Brain Res; 2007 Jan; 1129(1):89-99. PubMed ID: 17157278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes.
    Medina M; Avila J
    Expert Rev Neurother; 2013 May; 13(5):495-503. PubMed ID: 23621307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Glycogen Synthase Kinase-3: An Emerging Target in the Treatment of Traumatic Brain Injury.
    Shim SS; Stutzmann GE
    J Neurotrauma; 2016 Dec; 33(23):2065-2076. PubMed ID: 26979735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crocin may be useful to prevent or treatment of alcohol induced neurodegeneration and neurobehavioral sequels via modulation of CREB/BDNF and Akt/GSK signaling pathway.
    Motaghinejad M; Safari S; Feizipour S; Sadr S
    Med Hypotheses; 2019 Mar; 124():21-25. PubMed ID: 30798909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of Akt-GSK-3beta signaling and synaptic strength in phencyclidine-induced neurodegeneration.
    Lei G; Xia Y; Johnson KM
    Neuropsychopharmacology; 2008 May; 33(6):1343-53. PubMed ID: 17637606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a glycogen synthase kinase-3 inhibitor, lithium, in adenomatous polyposis coli mutant mice.
    Gould TD; Gray NA; Manji HK
    Pharmacol Res; 2003 Jul; 48(1):49-53. PubMed ID: 12770514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.
    Medina M; Avila J
    Curr Pharm Des; 2010; 16(25):2790-8. PubMed ID: 20698823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A myocyte enhancer factor 2D (MEF2D) kinase activated during neuronal apoptosis is a novel target inhibited by lithium.
    Linseman DA; Cornejo BJ; Le SS; Meintzer MK; Laessig TA; Bouchard RJ; Heidenreich KA
    J Neurochem; 2003 Jun; 85(6):1488-99. PubMed ID: 12787068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.